newsfilter
← Latest News
GlobeNewswire·

Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint

- Met Primary Endpoint With a Correct Localization Rate of 84.8–87.0%, Highlighting Strong Diagnostic Performance- Company Expects to Submit an NDA to the FDA in the Second Half of 2020- Conference...